Login to Your Account



Opsona's TLR Biology Will Get a $43M Shot in the Arm

By Cormac Sheridan
Staff Writer

Wednesday, May 1, 2013
DUBLIN, Ireland – Opsona Therapeutics Ltd. raised €33 million (US$43.2 million) in a Series C funding round to take forward a first-in-class Toll-like receptor 2 (TLR-2) inhibitor, OPN-305, into a Phase II trial for preventing delayed graft function (DGF) in high-risk kidney transplant patients.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription